IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 5745 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  NAVIGATE Here 
    Next article
    Previous article
    Table of Contents

 RESOURCE Links
    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed5448    
    Printed158    
    Emailed7    
    PDF Downloaded350    
    Comments [Add]    

Recommend this journal

 

 NET STUDY
Year : 2015  |  Volume : 81  |  Issue : 1  |  Page : 95-

Intravenous methylprednisolone pulse therapy in severe alopecia areata


1 Department of Dermatology, University of Medicine and Pharmacy "I. Hatieganu", Cluj Napoca, Romania
2 Department of Dermatology, University of Medicine and Pharmacy "I. Hatieganu", Cluj Napoca, Romania, Romania

Correspondence Address:
Dr. Rodica M Cosgarea
Department of Dermatology, Clinicilor Street 3-5, 400006, Cluj Napoca, Romania
Romania
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0378-6323.148608

Rights and Permissions

Background: Severe, extensive, therapy resistant alopecia areata represents a clinical challenge. Systemic corticosteroids are a therapeutic tool that still needs to be evaluated. Aim: The purpose of this study was to assess the efficacy and safety of methylprednisolone pulse therapy in alopecia areata and to find prognostic factors for a favourable outcome. Methods: A total of 32 patients with severe multifocal alopecia areata (more than 40% scalp hair loss), alopecia totalis, and alopecia universalis were treated with infusions of 500 mg methylprednisolone for 3 days every month for 3 consecutive months. The end point of the study was 12 months. Results: Of 32 patients, 26 (81.3%) reported a clinical response. Four patients (12.5%) showed complete hair regrowth, 6 patients (18.8%) showed >50% hair regrowth, ten (31.3%) had <50% hair regrowth, 6 (18.75%) were non responders, and another 6 patients (18.8%) had relapse after an initial regrowth. Multivariate analysis revealed that patients reporting at the first episode and those with multifocal disease had the best results. Conclusion: Methylprednisolone infusions represent a possible therapeutic option for patients with multifocal alopecia areata and those presenting with the first episode of the disease.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Online since 15th March '04
Published by Wolters Kluwer - Medknow